Evidence map›Paper›PMID 32412056›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Ibrutinib Is a Newly Recognized Host Factor for the Definition of Probable Invasive Pulmonary Mold Disease, Based on Off-target Effects, Unrelated to Its B-cell Immunosuppressant Activity.

Mario Luppi, Fabio Forghieri, Leonardo Potenza

Open access · greenAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Reply to Luppi et al.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Mario LuppiDivision of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero Universitaria Policlinico Modena, Modena, Italy.
Fabio ForghieriDivision of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero Universitaria Policlinico Modena, Modena, Italy.
Leonardo PotenzaDivision of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero Universitaria Policlinico Modena, Modena, Italy.
University of Modena and Reggio Emilia · ITPoliclinico di Modena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MycosesNeoplasmsAdenineB-LymphocytesConsensusHumansImmunosuppressive AgentsPiperidinesAdenineibrutinibImmunosuppressive AgentsPiperidines

Identifiers

PMID32412056
OpenAlexW3028171020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.